Skip to main content
. 2023 Oct 6;11(10):2716. doi: 10.3390/biomedicines11102716

Figure 3.

Figure 3

(A) IC50 of compounds 3a, 5b, doxorubicin and tamoxifen in MCF-7 breast cancer cells. (B) Lead compounds, 3a and 5b, produce loss of cell viability in MDAMB231, BT–549 and SUM159PT cells. The IC50 was calculated. Data represents triplicate determinations.